$71.66
0.46% today
NYSE, Feb 05, 04:16 pm CET
ISIN
US28176E1082
Symbol
EW

Edwards Lifesciences Stock price

$71.33
-2.21 3.01% 1M
+10.63 17.51% 6M
-2.70 3.65% YTD
-14.73 17.12% 1Y
-40.85 36.41% 3Y
-4.12 5.46% 5Y
+48.86 217.37% 10Y
NYSE, Closing price Tue, Feb 04 2025
-0.05 0.07%
ISIN
US28176E1082
Symbol
EW
Sector

Key metrics

Market capitalization $42.07b
Enterprise Value $38.39b
P/E (TTM) P/E ratio 10.29
EV/FCF (TTM) EV/FCF 74.48
EV/Sales (TTM) EV/Sales 6.54
P/S ratio (TTM) P/S ratio 7.16
P/B ratio (TTM) P/B ratio 4.41
Revenue growth (TTM) Revenue growth 0.92%
Revenue (TTM) Revenue $5.87b
EBIT (operating result TTM) EBIT $1.60b
Free Cash Flow (TTM) Free Cash Flow $515.50m
Cash position $4.45b
EPS (TTM) EPS $6.93
P/E forward 29.05
P/S forward 7.26
EV/Sales forward 6.63
Short interest 1.55%
Show more

Is Edwards Lifesciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Edwards Lifesciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a Edwards Lifesciences forecast:

15x Buy
44%
19x Hold
56%

Analyst Opinions

34 Analysts have issued a Edwards Lifesciences forecast:

Buy
44%
Hold
56%

Financial data from Edwards Lifesciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
5,873 5,873
1% 1%
100%
- Direct Costs 1,329 1,329
3% 3%
23%
4,544 4,544
2% 2%
77%
- Selling and Administrative Expenses 1,715 1,715
8% 8%
29%
- Research and Development Expense 1,081 1,081
5% 5%
18%
1,748 1,748
4% 4%
30%
- Depreciation and Amortization 149 149
9% 9%
3%
EBIT (Operating Income) EBIT 1,599 1,599
4% 4%
27%
Net Profit 4,159 4,159
191% 191%
71%

In millions USD.

Don't miss a Thing! We will send you all news about Edwards Lifesciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Edwards Lifesciences Stock News

Neutral
Business Wire
one day ago
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2024 after the market closes on Tuesday February 11, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live ...
Positive
Seeking Alpha
20 days ago
Texas Pacific Land and Taiwan Semiconductor Manufacturing were top contributors for both the quarter and the year, showcasing strong earnings growth and strategic market positioning. Despite Texas Pacific Land's strong performance, we sold our positions due to overvaluation driven by index additions, with plans to re-invest post-market correction. Edwards Lifesciences' EARLY TAVR trial results ...
Neutral
Business Wire
29 days ago
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be availabl...
More Edwards Lifesciences News

Company Profile

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Head office United States
CEO Bernard Zovighian
Employees 19,800
Founded 1958
Website www.edwards.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today